The Lancet's latest article reveals that Remegis is safe and effective in preventing migraines

Migraines are chronic neurological disorders characterized by recurrent headaches, usually one-sided headaches, bursts of headache, accompanied by fear of light, fear of sound, nausea, and vomiting.
more than 1 billion people worldwide suffer from migraines, three-quarters of them women.
current medication for migraines is generally divided into two categories - acute treatment and preventive treatment, which is used to relieve symptoms at the onset, and preventive medication, which reduces the frequency and severity of seizures.
However, most traditional oral preventive treatments (such as β-blockers, anti-epileptic drugs, and triceptic antidepressants) are not specifically developed for migraines and are generally less safe and resistant, as are clinically less patients.
recently, the Robert Croop team of Biohaven Pharmaceuticals in the United States published an article in The Lancet entitled "Oral Rimegepant for preventive treatment of migraine: a phase 2/3, randomized, double-blind, placebo-controlled trial" to study the effectiveness of oral remegyrgin in preventing migraines.
rheumeddine, an oral calcitonin gene-related peptide (CGRP) peptide antagonist, has been approved in the United States for acute treatment of migraines in adults.
in multiple randomized, placebo-controlled clinical trials, 75 mg doses of remegis were safe and effective.
there are currently four monoclonal antibodies targeting CGRP receptors or media as preventive treatments for migraines.
the purpose of this study was to compare the safety, toerability and effectiveness of taking remetrial and placebo every other day to prevent migraines.
team conducted a multicenter, randomized, double-blind, placebo-controlled trial at 92 research centers in the United States to assess the safety and effectiveness of remegis in migraine prevention treatment.
the study consisted of three phases, including a four-week observation period, a 12-week double-blind treatment period, and subsequent follow-up period.
eligible participants were men and women 18 years of age and older who had at least one year of precursor migraine history, no precursor migraine history, or chronic migraine, and had their first migraine before age 50.
participants must also have at least 4 (no more than 18) moderate or severe migraine episodes during the 3 months prior to the screening visit.
November 14, 2018 to August 30, 2019, the team recruited 747 adults with at least one year's history of migraines.
the participants were randomly assigned after a four-week observation period, with 373 receiving remetrial and 374 receiving matching placebos for 12 weeks the next day.
the main efficacy endpoint was a change in the average number of days of migraines per month over the last 4 weeks (9-12 weeks) compared to the 4-week observation period.
695 participants were included in the efficacy analysis, including 348 in the Remegis group and 347 in the placebo group.
9-12 weeks, the Remegis group outperformed the placebo group at the main endpoint of the change in the average number of migraine days per month.
compared to the observation period, the average number of migraine days per month was reduced by 4.3 days in patients in the Remegis group and by an average of 3.5 days in the placebo group over a significant difference over a period of 9-12 weeks.
741 participants were given the drug and included in the safety analysis.
133 (36%) of the 370 patients in the Remegis group reported adverse events and 133 (36%) out of 371 patients in the placebo group.
7 (2%) participants in the Remegis group and 4 (1%) in the placebo group suspended the study due to adverse events, during which time no patients died.
the results showed that taking Remetrius the next day was effective in preventing migraines and was safe to bear.
current preclinical studies have shown that long-term antagonists of CGRP pathps are not associated with headaches caused by drug overuse.
, the results of this study show the potential of Remegis in the preventive treatment of migraines.
the use of remegis in acute and preventive treatment of migraines may reduce the overall burden of migraine-related diseases.
。